Dr. Stephen Chang joined NYSCF in 2010 as the Vice President of Research and Development after serving as Chief Scientific Officer of Stemgent upon the company’s founding in 2008. Now, in his position as Senior Vice President for Strategic and Research Initiatives, he brings 30 years of experience to the development and utilization of large-scale induced pluripotent stem cells (IPSCs) and differentiated cell production in pre-clinical and clinical projects. He was previously the CEO of Multicell Technologies and continues as a director of this company. Dr. Chang is president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative lifesaving medications. He is also a board member of Histogen, Inc., a privately held company in regenerative medicine. Dr. Chang received his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine. Areas of research interest include translational applications of basic science to pharmaceutical products.